文献速递主动脉疾病

三十年来腹主动脉瘤患者心血管风险与药物管理评估

Assessing Cardiovascular Risk and Medication Management in Patients with Abdominal Aortic Aneurysm across Three Decades.
PubMed 文献 · Eur J Vasc Endovasc Surg · 2025-02-22

这项单中心回顾性队列研究纳入1989年1月至2023年7月阿姆斯特丹大学医学中心全部7957例腹主动脉瘤患者,评估六个时间段心血管合并症与药物处方的趋势及两年生存率。结果显示心血管合并症、药物处方和诊断年龄随时间增加,诊断时心血管药物处方率低,提示风险管理不足。

要点

  • 诊断时常见合并症为高血压(39.7%)、短暂性脑缺血发作(27.1%)和心肌梗死(17.5%)。
  • 常用药物为血小板抑制剂(40.5%)、β受体阻滞剂(28.9%)和他汀类(27.4%)。
  • 两年生存率为77.7%(95%CI 76.6-78.7%),全因死亡率随时间显著增加(log rank p < .001)。

核心结论

  • 腹主动脉瘤患者的心血管合并症、药物处方和诊断年龄随时间增加。
  • 诊断时心血管药物处方率低提示风险管理不足,强调需要更严格的心血管风险管理以降低死亡率。

研究设计与样本

  • 单中心回顾性队列研究,纳入1989年1月至2023年7月阿姆斯特丹大学医学中心全部腹主动脉瘤患者,共7957例(78.8%男性;平均年龄71.8±9.9岁)。
  • 按六个时间段评估诊断时心血管合并症和药物处方的趋势:1989-1998、1999-2003、2004-2008、2009-2013、2014-2018和2019-2023。
  • 分析两年生存率,并使用多变量Cox比例风险模型检验心血管合并症和药物处方与全因死亡率的关联。

主要发现

  • 诊断时常见心血管合并症为高血压(39.7%)、短暂性脑缺血发作(27.1%)和心肌梗死(17.5%)。
  • 常用处方药物为血小板抑制剂(40.5%)、β受体阻滞剂(28.9%)和他汀类(27.4%)。
  • 随时间推移,心血管合并症、药物处方和诊断年龄均增加。
  • 两年生存率为77.7%(95%CI 76.6-78.7%),全因死亡率随时间显著增加(log rank p < .001)。
  • 高龄(p < .001;HR 1.065)、慢性肾功能衰竭(p < .001;HR 1.545)、心力衰竭(p = .002;HR 1.198)和慢性阻塞性肺疾病(p < .001;HR 1.354)与死亡风险增加相关,而血脂异常(p < .001;HR 0.818)与风险降低相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Patients with abdominal aortic aneurysm (AAA) have higher mortality rates due to increased cardiovascular risk. This retrospective study provides an overview of cardiovascular comorbidities and medication prescriptions in patients with AAA over different time periods. METHODS: This single centre, retrospective cohort study included all AAA patients at the Amsterdam University Medical Centres from January 1989 to July 2023. Trends in cardiovascular comorbidities and medication prescriptions at AAA diagnosis were assessed across six periods: 1989 - 1998, 1999 - 2003, 2004 - 2008, 2009 - 2013, 2014 - 2018, and 2019 - 2023. Two year survival rates were analysed, and a multivariable Cox proportional hazards model was used to examine the association between cardiovascular comorbidities and medication prescriptions with all-cause mortality. RESULTS: The study included 7 957 patients (78.8% male; mean age 71.8 ± 9.9 years). Common cardiovascular comorbidities at AAA diagnosis were hypertension (39.7%), transient ischaemic attack (27.1%), and myocardial infarction (17.5%). Frequently prescribed medications included platelet inhibitors (40.5%), beta blockers (28.9%), and statins (27.4%). Over time, cardiovascular comorbidities, medication prescriptions, and age at diagnosis increased. The two year survival rate was 77.7% (95% confidence interval 76.6 - 78.7%), with a significant increase in all-cause mortality over time (log rank p < .001). Advanced age (p < .001; hazard ratio [HR] 1.065), chronic renal failure (p < .001; HR 1.545), heart failure (p = .002; HR 1.198), and chronic obstructive pulmonary disease (p < .001; HR 1.354) were associated with increased mortality risk, whereas dyslipidaemia (p < .001; HR 0.818) was associated with a decreased risk. Insulin (p < .001; HR 1.373) and diuretic use (p < .001; HR 1.223) were associated with increased mortality risk, whereas platelet inhibitors (p = .006; HR 0.899) and nitrates (p = .031; HR 0.858) were linked to a decreased risk. CONCLUSION: Cardiovascular comorbidities, medication prescriptions and age of AAA diagnosis have increased over time in patients with AAA. Low cardiovascular medication prescription rates at diagnosis suggest inadequate risk management, emphasising the need for stricter cardiovascular risk management to reduce the mortality rate.

来源:Eur J Vasc Endovasc Surg,查看原文。版权归原作者所有。

引用

  1. van Knippenberg SEM, Thiermann NJS, Atazadah M, et al. Assessing Cardiovascular Risk and Medication Management in Patients with Abdominal Aortic Aneurysm across Three Decades. Eur J Vasc Endovasc Surg. 2025. PMID: 39993555. doi:10.1016/j.ejvs.2025.02.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。